Sunesis Pharmaceuticals Inc., of South San Francisco, priced underwritten offerings of about 9.5 million shares of its common stock at a price of 84 cents each and 20,200 shares of its nonvoting series B convertible preferred stock at $840 each. Sunesis expects to receive combined gross proceeds of about $25 million from the offerings.